Covaxin Phase III trials hit halfway mark with 13K volunteers

Covaxin, India's first indigenous Covid-19 vaccine being developed by Hyderabad-based Bharat Biotech, has been successful in roping in 13,000 volunteers for its Phase III trials, which is half the number of volunteers targeted for the efficacy studies. The Phase III human clinical trials of Covaxin began in mid-November with NIMS Hyderabad, making it the first and only Phase III efficacy studies for a Covid-10 vaccine in India.
http://dlvr.it/Rp7xGQ